Author: paroukatos

Stephen C. Benson, Harrihar A. Pershadsingh, Christopher I. Ho, Amar Chittiboyina, Prashant Desai, Michal Pravenec, Nianning Qi, Jiaming Wang, Mitchell A. Avery, Theodore W. Kurtz Abstract The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of...

Jutta M. Nagel1, Anne B. Tietz1, Burkhard Gfke, Klaus G. Parhofer Medizinische Klinik und Poliklinik II, Klinikum Großhadern, Ludwig-Maximilians-Universita¨ t, 81377 Munich, Germany Received 4 January 2006; accepted 3 April 2006 Abstract Intervention studies have shown that angiotensin receptor blocker therapy may reduce the incidence of type 2...

Giuseppe Mancia, Michele Bombelli, Giovanni Corrao, Rita Facchetti, Fabiana Madotto, Cristina Giannattasio, Fosca Quarti Trevano, Guido Grassi, Alberto Zanchetti, Roberto Sega Abstract-The prevalence of the metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel III criteria) and its relationships with daily life blood pressures, cardiac damage,...

Implications for treating insulinresistant hypertension and cardiovascular disease The angiotensin II type 1 receptor blocker (ARB) telmisartan was reported to activate the peroxisome proliferator-activated receptor-_ (PPAR_) in transactivation assays, whereas other ARBs, with the possible exception of irbesartan, did not (1). Telmisartan also induced adipogenesis and...

Theodore W. Kurtz, MD epartment of Laboratory Medicine, University of California, San Francisco, California, USA ABSTRACT The metabolic syndrome is characterized by the clustering of insulin resistance, dyslipidemia, and hypertension and is associated with increased risk of cardiovascular disease and type 2 diabetes mellitus. However, older antihypertensive agents...

T.W. Kurtz Abstract Hypertension commonly occurs as part of a genetically complex disorder of carbohydrate and lipid metabolism known as the metabolic syndrome. Most current antihypertensive drugs appear ineffective against the metabolic syndrome, which is a strong predictor of cardiovascular disease and death in affected patients. Angiotensin...

TheodoreW. Kurtza and Michal Pravenecb Several lines of evidence suggest that angiotensinconverting enzyme (ACE) inhibitors and some angiotensin II receptor blockers (ARBs) may improve insulin sensitivity and decrease the risk for type 2 diabetes. It is widely assumed that the potential antidiabetic properties of these agents...

Spyridon Koulouris, MD, PhD, Phivos Symeonides, MD, Konstantinos Triantafyllou, MD, Georgios Ioannidis, MD, Ilias Karabinos, MD, Theofanis Katostaras, PhD, Mahmud El-Ali, MD, Theodoros Theodoridis, MD, Ekaterini Vratsista, MD, Nikolaos Thalassinos, MD, Vassiliki Kokkinou, MD, Ioannis Nanas, MD, PhD, Stamatios Stamatelopoulos, MD, PhD, and Pavlos Toutouzas,...

Michael Schupp, BPharm; Jürgen Janke, PhD; Ronald Clasen, BPharm; Thomas Unger, MD; Ulrich Kintscher, MD Background: Αngiotensin type 1 receptor (AT1R) blockers (ARB) have been shown to reduce the incidence of type 2 diabetes mellitus by an unknown molecular mechanism. The peroxisome proliferator-activated receptor-_ (PPAR_) is the...

Introduction Evidence from a range of excellent clinical trials proves that lowering BP with several classes of antihypertensive drugs, including angiotensin II type 1 receptor blockers (ARBs), will reduce the complications of hypertension. ARBs, along with other antihypertensives, are beneficial in reducing stroke, coronary vascular disease...